论文部分内容阅读
目的探讨抗肿瘤坏死因子单克隆抗体infliximab的皮肤不良反应。方法在一项2个中心的开放性研究中,对infliximab治疗活动性强直性脊柱炎的安全性进行评估,所有患者在0、2、6周静脉输注infliximab5mg/kg,并随诊观察至10周,对出现皮肤不良反应的患者进行治疗,直至病情缓解。结果63例患者纳入研究,7例(11%)出现皮肤病变,包括毛囊炎、皮下脂肪瘤感染、足癣各1例,荨麻疹、迟发过敏性反应性皮炎伴严重脱发各2例,其中1例发生荨麻疹时伴有呼吸困难,未完成第3次液体的输注,另外2例迟发过敏性反应性皮炎病例为严重不良事件。结论Infliximab的皮肤不良反应常见,临床表现多样,多为轻度至中度,少数为重度。随着该药在临床的推广应用,应对其皮肤不良反应引起足够重视。
Objective To investigate the skin adverse reactions of anti-tumor necrosis factor monoclonal antibody infliximab. Methods The safety of infliximab in the treatment of ankylosing spondylitis was evaluated in a 2-center open-label study. Infliximab 5 mg / kg was infused intravenously at 0, 2, and 6 weeks in all patients and was observed up to 10 Week, the skin adverse reactions in patients with treatment, until the disease remission. Results Sixty-three patients were enrolled in the study, and dermatologic lesions were observed in seven patients (11%), including folliculitis, subcutaneous lipoma, tinea pedis, urticaria, and delayed-onset allergic dermatitis with severe hair loss in two 1 case of urticaria with dyspnea, did not complete the infusion of the third liquid, and the other two cases of late-onset allergic dermatitis cases of serious adverse events. Conclusions Infliximab has common skin adverse reactions, with various clinical manifestations, mostly mild to moderate and few severe. With the promotion of the drug in clinical application, should pay due attention to the adverse reactions of the skin.